• DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Press releases

Chagas disease: Shorter treatment just as effective as longer one, according to study in Bolivia published by The Lancet

The ‘game-changing’ findings pave the way for the adoption of a new regimen with fewer side effects and improved adherence for people living with Chagas disease

Home > Press releases

Chagas disease: Shorter treatment just as effective as longer one, according to study in Bolivia published by The Lancet

The ‘game-changing’ findings pave the way for the adoption of a new regimen with fewer side effects and improved adherence for people living with Chagas disease

Nurse holding a test tube
Cochabamba / Rio de Janeiro / Barcelona — 6 Apr 2021
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print
  • English
    • English
    • Español
    • Português
    • 日本語

A two-week treatment with the antiparasitic drug benznidazole for adults with chronic Chagas disease has similar efficacy and significantly fewer adverse effects than the current standard eight-week treatment, according to a study published by The Lancet Infectious Diseases.

These results are extracted from a Phase II clinical trial that was carried out in three centres in Bolivia, led by the Drugs for Neglected Diseases initiative (DNDi) and funded by the Global Health Innovative Technology Fund (GHIT).

‘A shorter treatment that is just as effective and much safer than the current one could be a game-changer for people with Chagas disease, who live for years with this debilitating disease,’ said Dr Faustino Torrico, co-principal investigator of the trial and President of the CEADES Foundation.

The trial was carried out between 2016 and 2018, in cooperation with many partners around the globe, including the Bolivian non-profit CEADES (Science and Applied Studies Foundation for Health and Environment Development), the Barcelona Institute for Global Health (ISGlobal), a centre supported by the ”La Caixa” Foundation, the Japanese pharmaceutical company Eisai Co., Ltd., and the Argentinian pharmaceutical company Elea.

Chagas disease affects an estimated six million people globally and can cause irreversible, life-threatening damage to the heart and other vital organs if not treated. Current treatment with benznidazole, one of the two drugs used to treat the disease, is effective but has limitations: the treatment course lasts 60 days and around 20% of patients stop it due to serious side effects, which include gastric intolerance, skin rashes, and neuromuscular problems.  

‘This was the first placebo-controlled study to compare different durations and doses of treatment with benznidazole, alone or in combination with fosravuconazole (E1224),’ said Joaquim Gascon, co-principal investigator and Director of the Chagas Initiative at ISGlobal.

Benznidazole was provided by Elea and fosravuconazole (E1224) was provided by Eisai Co., Ltd.

‘Although we could not verify the efficacy of the combination treatment of benznidazole and fosravuconazole (E1224) compared to treatment with benznidazole alone, the study confirmed the new regimen, with fewer adverse effects, which has potential to be a new standard treatment. We are pleased to have contributed to the creation of this evidence. Based on our human health care (hhc) corporate philosophy, we will continue to work with public and private partners including DNDi for the elimination of NTDs,’ said Dr Kappei Tsukahara, Vice President, Chief Data Officer and Head of Tsukuba Research Laboratories at Eisai Co., Ltd.

The objective of the BENDITA (Benznidazole New Doses Improved Treatment & Therapeutic Associations) clinical trial was to find regimens that are as effective as the standard treatment while producing fewer side effects to improve patient adherence to treatment. ‘This study provides hope for people affected by this neglected disease, as a shorter treatment will remove some concerns of caregivers and patients and will improve treatment adoption,’ said Sergio Sosa Estani, Head of the Chagas Clinical Programme at DNDi and researcher at CONICET (National Scientific and Technical Research Council) in Argentina.

Confirmatory studies with a larger number of patients in Argentina and other countries will validate these findings before the new regimen can be adopted by Chagas patients. DNDi will soon launch a Phase III clinical trial in Argentina in partnership with ELEA-Phoenix and Mundo Sano Foundation to confirm the efficacy and the safety of this two-week regimen of benznidazole.

This upcoming study should also contribute to simplifying the treatment of young girls and woman of child-bearing age to prevent congenital transmission from previously treated mothers to their babies. As mothers can transmit Chagas disease to their children, the trial could help lead to the elimination of Chagas disease as a public health problem, which is one of the World Health Organization’s Neglected Tropical Disease (NTD) Roadmap objectives for the next decade.

‘This is truly a remarkable achievement made possible by international collaboration. With this new finding, we opened up a new way to provide a new shorter regimen for patients. We appreciate patients, their families, healthcare professionals, and all the partners who joined the BENDITA study. We also thank Eisai for providing their drug fosravuconazole (E1224) for the combination treatment arms in the clinical trial to compare efficacy and safety,’ said Ms. Catherine Ohura, the CEO and Executive Director of GHIT.

For this study, DNDi received financial support from the Global Health Innovative Technology Fund, Japan; the UK Department for International Development (UK Aid); the German Federal Ministry of Education and Research through KfW; the Dutch Ministry of Foreign Affairs; the Brazilian Ministry of Health; the Associação Bem-Te-Vi Diversidade, Brazil; the Fundação Oswaldo Cruz (Fiocruz), Brazil; and the Starr International Foundation, Switzerland.

For its overall mission, DNDi also receives funding from the Swiss Agency for Development and Cooperation, Switzerland and Médecins Sans Frontières International. Non-conventional serology assays were performed at the Biomolecule Analysis Core Facility (currently, Biomolecule Analysis and Omics Unit) at the Border Biomedical Research Center, University of Texas at El Paso, funded by the National Institute on Minority Health and Health Disparities.

About DNDi

A not-for-profit research and development organization, DNDi works to deliver new treatments for neglected patients, those living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, and hepatitis C. DNDi is also coordinating a clinical trial to find treatments for mild-to-moderate COVID-19 cases in Africa. Since its inception in 2003, DNDi has delivered eight new treatments to date, including new drug combinations for kala-azar, two fixed-dose antimalarials, and DNDi’s first successfully developed new chemical entity, fexinidazole, approved in 2018 for the treatment of both stages of sleeping sickness. dndi.org

Media contact

DNDi Latin America
Marcela Dobarro
mdobarro@dndi.org
+55 21 981149429

DNDi Geneva
Frédéric Ojardias
fojardias@dndi.org  
+41 79 431 62 16

Photo credit: Ana Ferreira-DNDi

Clinical trials Chagas disease Latin America

Read, watch, share

Loading...
Lab activities
Press releases
29 Jun 2022

DNDi welcomes new PAHO recommendations for the treatment of leishmaniasis in the Americas

Publications
16 Jun 2022

DNDi‘s Commitment to the Kigali Declaration

Caregiver prepares 4-in-1 HIV treatment for child
Press releases
14 Jun 2022

Cipla and DNDi launch child-friendly 4-in-1 antiretroviral treatment for young children living with HIV in South Africa

Nurse with HIV-VL patient
Publications
8 Jun 2022

The Science Explained: Evaluating new treatment regimens for visceral leishmaniasis in people living with HIV in India and Ethiopia

Doctor with a patient
Press releases
8 Jun 2022

New WHO treatment guidelines offer hope for people co-infected with visceral leishmaniasis and HIV

Doctor talking with patient during a consultation
Press releases
1 Jun 2022

Thai partners unite with DNDi to improve access to treatments and diagnostics for people with hepatitis C in Thailand

Statements
24 May 2022

DNDi interventions at the 75th World Health Assembly

Hand holding pill
Publications
23 May 2022

DNDi briefing document: Best science for all

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi logo
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesNo description
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
CookieDurationDescription
_hjSessionUser_11288441 yearNo description
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo